panobinostat
Overview
Panobinostat is a pan-deacetylase (HDAC) inhibitor approved for relapsed/refractory multiple myeloma in combination with bortezomib. In sarcoma it has been evaluated in functional drug screens and in matched-therapy case series.
Evidence in the corpus
- In the UCLA PDTO sarcoma screen, bortezomib + panobinostat was among the top-ranked matched regimens tested in a patient-level clinical application (n=5 matched-therapy patients). Normalized organoid viability correlated with time-to-next-treatment across the n=5 matched cohort (R²=0.921, p=0.009). PMID:39305899
- Chordoma PDTOs were significantly less sensitive to bortezomib (p=1.8×10⁻⁵) than the pan-sarcoma average; panobinostat was not explicitly tested in a subtype-stratified analysis in the reported data. PMID:39305899
- Included in the CCLE pharmacogenomic screen across 947 cancer cell lines; sensitivity correlated with genomic features via elastic-net regression PMID:22460905
- Used in combination with 5-day decitabine in 3 patients in the WashU AML/MDS trial extension cohort (NCT01687400, N=116); panobinostat 10 mg three times weekly was combined with decitabine at Washington University in St. Louis as part of an extended protocol evaluation PMID:27959731
Resistance mechanisms
- Not reported in corpus.
Cancer types (linked)
Sources
- PMID:39305899 — Duminuco et al. 2024, UCLA PDTO sarcoma functional screen; bortezomib + panobinostat matched-therapy case series.
- PMID:22460905
- PMID:27959731 — Welch et al. 2016, NEJM. WashU 10-day decitabine AML/MDS trial; panobinostat combined with 5-day decitabine in 3 extension-cohort patients.
This page was processed by entity-page-writer on 2026-05-15.